Euroapi plans initiatives to support production of APIs in France and Europe

Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026

Croma-Pharma enrolls first patient in hyaluronic acid dermal filler clinical trial in China

The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease

Milla receives first cycle FDA approval for Dexmedetomidine Hydrochloride Injection

Asence Pharma commences new plant at Ranoli, Vadodara

The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement

Cosette Pharmaceuticals acquires Intrarosa from Endoceutics

Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product

USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada

The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab

Eugia Pharma receives USFDA approval for Carboprost Tromethamine Injection

The product is expected to be launched in June 2023